A product marketing veteran with an ophthalmology focus at companies such as Santen, Merck and Pharmacia WALTHAM, Mass., Nov. 01, 2017 — EyeGate Pharmaceuticals, Inc. […]
read moreWALTHAM, Mass., Oct. 23, 2017 — EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company focused on developing and commercializing products […]
read moreWALTHAM, Mass., Sept. 11, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company focused on developing and commercializing products […]
read moreWALTHAM, Mass., Sept. 05, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company focused on developing and commercializing products […]
read moreWALTHAM, Mass., Aug. 07, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on developing and commercializing […]
read moreWALTHAM, Mass., Aug. 01, 2017 — EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products […]
read moreWALTHAM, Mass., June 09, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products […]
read moreWALTHAM, Mass., May 22, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products […]
read moreWALTHAM, Mass., May 08, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on developing and commercializing […]
read moreWALTHAM, Mass., May 04, 2017 – EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on developing and commercializing […]
read more